2007 NSTI Nanotechnology Conference and Trade Show - Nanotech 2007 - 10th Annual
Thomas Schluep

Thomas Schluep

Chief Scientific Officer, Insert Therapeutics

Thomas Schluep, Sc.D. is the Chief Scientific Officer at Insert Therapeutics, a privately held biopharmaceutical company. He is responsible for Insert’s drug discovery and development programs. Insert is using its proprietary polymeric transport system, Cyclosert™, to design, develop and commercialize nanoparticle-enhanced small-molecule therapeutics. Insert’s lead drug candidate, a combination of its linear, cylodextrin-based polymer and the anti-cancer compound camptothecin, entered the clinic in 2006.

Prior to joining Insert in 2004, Dr. Schluep was in charge of the non-viral gene therapy program at Canji, Inc., a wholly owned subsidiary of Schering-Plough. While at Canji, he held multiple positions of increasing responsibility in the development, manufacture, and analytical testing of non-viral and adenoviral gene therapy vectors. A constant interest of Dr. Schluep has been to understand the role nanotechnology can play in enhancing the efficacy and therapeutic index of a wide variety of therapeutics. He holds a Sc.D. in Process Engineering and an MS in Biotechnology, both from the Swiss Federal Institute of Technology in Zurich, Switzerland.

Speaking in the Nanotech for Investors Summit.


View Confimed Speakers

Back to Conferences & Symposia

 
 

Names, and logos of other organizations are the property of those organizations and not of NSTI.
This event is not open to the general public and NSTI reserves the right to refuse admission and participation to any individual.